Financial Trends -- 7/10

Textbook worse-to-better inflection. After two years of declining revenue (GRAIL spin, China collapse, NIH overhang), top-line YoY turned positive in 2H25 and is accelerating (+0.4% → +5.0% → +4.8%). FCF YoY just flipped positive in 26Q1 (+20.7%), annual FCF margin has tripled (7.4% → 21.4%), core operating margin expanded from low-single-digits to ~22-24%, and the share count is flat-to-declining (no dilution, new $1.5B buyback). What holds this back from an 8-9: gross margin is range-bound (flat, not +100bps) and the FCF YoY acceleration is one quarter old off easy comps. No penalty modifiers apply. Weight: 25%

26Q1 Revenue

$1.09B

src | +4.8% YoY | Accelerating

Gross Margin

~68%

Range-bound 67-70% | Flat

FCF Margin

21.4%

Tripled off 2022 | Inflecting

Share Count

Flat/Down

~158M | $1.5B buyback

Quarterly Revenue Trajectory ($M) -- 8 Contiguous Quarters

Quarter	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
Total Revenue	$1,112M	$1,080M	$1,104M	$1,041M	$1,059M	$1,084M	$1,159M	$1,091M
YoY	-5.4%	-3.5%	-1.6%	-3.3%	-4.8%	+0.4%	+5.0%	+4.8%

Clear inflection off a trough: -4.8% (25Q2) to +5.0% / +4.8% (25Q4 / 26Q1). The YoY rate is accelerating — the trough was 1H25 (-3% to -5%) and the last three prints are +0.4% / +5.0% / +4.8%. Drivers: NovaSeq X consumables pull-through (82% of volume / 55% of revenue on X), clinical consumables +20% ex-China, and lapping of the worst Greater China declines (now <5% of mix). 26Q1 revenue +4.8% beat ~$1,070M Street by +2.0%; Adj EPS $1.15 beat $1.05 by +9.5%.

Non-GAAP Gross Profit ($M)

Metric	25Q1	26Q1	YoY
Non-GAAP Gross Profit	$702M	$744M	+6.0%
Non-GAAP Gross Margin	67.4%	68.2%	+80 bps

Gross profit dollars grew +6.0%, but the margin is range-bound. Non-GAAP gross margin has oscillated between 67% and 70% across the last eight quarters with no sustained 100bp+ expansion — a mild positive bias versus the 2023 trough (~65%) but not enough to credit margin expansion. This flatness is the single biggest reason the dimension is capped below an 8.

Annual Financial Summary (FY ends December)

Metric	FY2021	FY2022	FY2023	FY2024	FY2025
Total Revenue ($M)	$4,526M	$4,584M	$4,504M	$4,372M	$4,343M
Rev YoY	—	+1.3%	-1.7%	-2.9%	-0.7%
Non-GAAP Gross Profit ($M)	$3,225M	$3,145M	$2,940M	$2,990M	$2,964M
Non-GAAP GM %	71.3%	68.6%	65.3%	68.4%	68.2%
Non-GAAP Net Income ($M)	$892M	$336M	$137M	$390M	$756M
Free Cash Flow ($M)	$337M	$106M	$283M	$695M	$931M
FCF margin %	7.4%	2.3%	6.3%	15.9%	21.4%
Adj Diluted EPS (Core) ($)	—	—	—	$4.16	$4.84
GAAP Diluted Shares (M)	n/a	157	158	159	~158

Key trends

Worse-to-better revenue inflection: Annual revenue slid from a $4.58B peak (2022) to $4.34B (2025), but the quarterly exit rate (+5.0% / +4.8%) and the FY26 guide (+4–6%) confirm reacceleration off the trough
FCF is the standout: Annual FCF margin 2.3% (2022) → 6.3% → 15.9% → 21.4% (2025); absolute FCF nearly tripled ($337M → $931M vs 2021) and YoY flipped to +20.7% in 26Q1
Operating margin expanding: Core Non-GAAP op margin moved from 3.1% (24Q1) into the 22-24% band as restructuring/cost-out landed — revenue growing with op income growing
No dilution: Diluted shares flat ~157-159M with a new $1.5B buyback; net debt/EBITDA ~1.0x, debt not growing faster than revenue

Segment Revenue Mix (26Q1, $M)

Segment	26Q1 Revenue	% of Total	Theme Growth
Sequencing Consumables	$726M	~66.5%	Clinical +20% ex-China
Sequencing Service & Other	~$151M	~13.8%	+7% YoY
Sequencing Instruments	$118M	~10.8%	+9% YoY (supply-constrained)
Microarrays / Other	$71M	~8.7%	-20% organic (DTC)
Total	$1,091M	100%	+4.8% reported

Consumables (~66% of revenue) are the annuity where the moat lives. The razor/razor-blade model: instruments seed a locked-in recurring consumables stream. Clinical consumables are compounding ~+20% ex-China while the legacy microarray/DTC tail (-20% organic) is a small drag. Reported +4.8% versus +1.2% organic reflects the SomaLogic bolt-on.

Free Cash Flow ($M) -- The Inflection

Metric	FY2021	FY2022	FY2023	FY2024	FY2025
Free Cash Flow	$337M	$106M	$283M	$695M	$931M
FCF YoY	—	-68.5%	+167.0%	+145.6%	+34.0%
FCF margin %	7.4%	2.3%	6.3%	15.9%	21.4%

FCF positive every year and strongly growing. Annual FCF margin has tripled from 2.3% (2022) to 21.4% (2025) as cost-out and post-GRAIL discipline landed. The 26Q1 YoY flip to +20.7% — after four straight down quarters (-17% to -4%) — is the first quarterly confirmation of the inflection. It is one quarter old off easy comps, which is why the dimension is capped below 8 rather than higher. FCF is a hard gate and it is cleared: YES.

Penalty Modifier Check -- None Applied

Modifier	Detail	Penalty
Negative FCF	No — FCF positive and growing every year ($337M 2021 → $931M 2025)	None
Dilution >10%	No — diluted shares flat ~157-159M; new $1.5B buyback authorized	None
Revenue up, op income down	No — both growing; core op margin expanded into the 22-24% band	None
Debt growing faster than revenue 3+ qtrs	No — net debt/EBITDA ~1.0x, gross leverage fell to ~1.6x	None

Score Rationale

Score of 7/10 reflects a strong worse-to-better inflection, meaningfully above the "5 = stable" anchor but short of a 9-10. No penalty modifiers applied.

Supports 7/10:

Revenue YoY accelerating off a 1H25 trough (+0.4% / +5.0% / +4.8% last three quarters; FY26 guide +4–6%)
FCF YoY flipped positive (+20.7% in 26Q1) and FCF margin tripled (7.4% → 21.4%)
Core operating margin expanded from 3.1% (24Q1) into the 22-24% band
Share count flat-to-declining with no dilution and a new $1.5B buyback
Composite hard gate cleared — positiveGrowingFcf: YES

What caps it below 8:

Gross margin is range-bound 67-70% (flat, not expanding 100+bps)
The FCF YoY reacceleration is a single quarter old off easy comps rather than a multi-quarter trend
Annual revenue was still slightly negative in 2025 (-0.7%) — the inflection is young

Data sourced from Daloopa. Fiscal year ends December 31. All financials in USD. Consolidated EBITDA FY22-FY24 distorted by GRAIL impairments; Core Illumina and FCF are the relevant series.